127 related articles for article (PubMed ID: 32709671)
1.
Nguyen NC; Beriwal S; Moon CH; Furlan A; Mountz JM; Rangaswamy B
J Nucl Med Technol; 2020 Dec; 48(4):331-335. PubMed ID: 32709671
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the prognostic value of F-18 FDG PET/CT metabolic parameters of primary tumors and MRI findings in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy.
Dag Z; Yilmaz B; Dogan AK; Aksan DU; Ozkurt H; Kızılkaya HO; Arslan D
Brachytherapy; 2019; 18(2):154-162. PubMed ID: 30594422
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic efficiency of whole-body
Steiner A; Narva S; Rinta-Kiikka I; Hietanen S; Hynninen J; Virtanen J
Cancer Imaging; 2021 Jan; 21(1):16. PubMed ID: 33482909
[TBL] [Abstract][Full Text] [Related]
4. Measurement Repeatability of
Fraum TJ; Fowler KJ; Crandall JP; Laforest RA; Salter A; An H; Jacobs MA; Grigsby PW; Dehdashti F; Wahl RL
J Nucl Med; 2019 Aug; 60(8):1080-1086. PubMed ID: 30733325
[TBL] [Abstract][Full Text] [Related]
5. Relative clinical utility of simultaneous
Gong J; Liu H; Bao Z; Bian L; Li X; Meng Y
J Int Med Res; 2021 Jun; 49(6):3000605211019190. PubMed ID: 34162259
[TBL] [Abstract][Full Text] [Related]
6. Concordance of FDG PET/CT metabolic tumour volume versus DW-MRI functional tumour volume with T2-weighted anatomical tumour volume in cervical cancer.
Lai AYT; Perucho JAU; Xu X; Hui ES; Lee EYP
BMC Cancer; 2017 Dec; 17(1):825. PubMed ID: 29207964
[TBL] [Abstract][Full Text] [Related]
7. Prospective comparison of
Kirchner J; Sawicki LM; Nensa F; Schaarschmidt BM; Reis H; Ingenwerth M; Bogner S; Aigner C; Buchbender C; Umutlu L; Antoch G; Herrmann K; Heusch P
Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):437-445. PubMed ID: 30074073
[TBL] [Abstract][Full Text] [Related]
8. Role of 18F-FDG PET/CT in detecting pelvic lymph-node metastases in patients with early-stage uterine cervical cancer: comparison with MRI findings.
Lv K; Guo HM; Lu YJ; Wu ZX; Zhang K; Han JK
Nucl Med Commun; 2014 Dec; 35(12):1204-11. PubMed ID: 25222911
[TBL] [Abstract][Full Text] [Related]
9. Comparison of
Sarabhai T; Schaarschmidt BM; Wetter A; Kirchner J; Aktas B; Forsting M; Ruhlmann V; Herrmann K; Umutlu L; Grueneisen J
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):67-76. PubMed ID: 28840302
[TBL] [Abstract][Full Text] [Related]
10. Pre-treatment prediction of early response to chemoradiotherapy by quantitative analysis of baseline staging FDG-PET/CT and MRI in locally advanced cervical cancer.
Min LA; Ackermans LL; Nowee ME; Griethuysen JJV; Roberti S; Maas M; Vogel WV; Beets-Tan RG; Lambregts DM
Acta Radiol; 2021 Jul; 62(7):940-948. PubMed ID: 32722967
[TBL] [Abstract][Full Text] [Related]
11. The impact of
Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
[TBL] [Abstract][Full Text] [Related]
12. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
[TBL] [Abstract][Full Text] [Related]
13. Comparison of hybrid FDG PET/MRI compared with PET/CT in colorectal cancer staging and restaging: a pilot study.
Paspulati RM; Partovi S; Herrmann KA; Krishnamurthi S; Delaney CP; Nguyen NC
Abdom Imaging; 2015 Aug; 40(6):1415-25. PubMed ID: 26112492
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the Role of F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scanning in the Staging of Patients With Stage IIIB Cervical Carcinoma and the Impact on Treatment Decisions.
Morkel M; Ellmann A; Warwick J; Simonds H
Int J Gynecol Cancer; 2018 Feb; 28(2):379-384. PubMed ID: 29324535
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG-PET/CT is of limited value in primary staging of early stage cervical cancer.
Driscoll DO; Halpenny D; Johnston C; Sheehy N; Keogan M
Abdom Imaging; 2015 Jan; 40(1):127-33. PubMed ID: 25015401
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. Comparison of FDG PET/CT and MRI in lymph node staging of endometrial cancer.
Kim HJ; Cho A; Yun M; Kim YT; Kang WJ
Ann Nucl Med; 2016 Feb; 30(2):104-13. PubMed ID: 26546334
[TBL] [Abstract][Full Text] [Related]
18. High standardized uptake values of
Yang Z; Wu JR; Wei LL; Liao GX; Yang CJ; Jin GQ; Xiao GY; Su DK
Hell J Nucl Med; 2019; 22(2):96-102. PubMed ID: 31273350
[TBL] [Abstract][Full Text] [Related]
19. Limited additional value of cervical ultrasonography over a negative 18F-FDG PET/CT for diagnosing cervical lymph node metastases in patients with esophageal cancer: a systematic review and meta-analysis.
Goense L; Meziani J; van Rossum PSN; Wessels FJ; Meijer GJ; Lam MGEH; van Hillegersberg R; Ruurda JP
Nucl Med Commun; 2018 Jul; 39(7):645-651. PubMed ID: 29672463
[TBL] [Abstract][Full Text] [Related]
20. Fusion of PET and MRI for staging of uterine cervical cancer: comparison with contrast-enhanced (18)F-FDG PET/CT and pelvic MRI.
Kitajima K; Suenaga Y; Ueno Y; Kanda T; Maeda T; Deguchi M; Ebina Y; Yamada H; Takahashi S; Sugimura K
Clin Imaging; 2014; 38(4):464-469. PubMed ID: 24642250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
